黑料吃瓜群网

Project to improve treatments for children's muscle diseases


Friday, 22 September, 2023

Project to improve treatments for children's muscle diseases

An Australian biobank will be established to improve and discover treatments for children with genetic muscle diseases.

Co-led by , and , the National Muscle Disease Bio-databank will advance research into understanding why children develop genetic muscle diseases.

The national research team will study the genes, cells and proteins in patient samples to understand how muscle is affected by disease. Housed at Murdoch Children鈥檚 Research Institute, the databank will store blood test and skin biopsy samples from children across Australia with genetic muscle diseases.

Genetic muscle diseases, spanning dystrophies and myopathies, are characterised by severe muscle weakness, usually from infancy, that impacts swallowing and breathing and leads to eye problems and learning difficulties. The project forms part of a $2.5 million Medical Research Future Fund grant awarded to the team for research into congenital muscle diseases.

Murdoch Children鈥檚 said there was an unmet need for affordable treatments that could be fast-tracked into clinical trials.

鈥淭his bio-databank will advance our knowledge of disease mechanisms and has the real potential to discover new and better treatments and fast-track discoveries.鈥

鈥淭he financial cost per year for genetic therapies and loss of productivity for those with muscular dystrophy is $435 million due to a lack of effective treatments,鈥 said Monash University鈥檚 , noting that genetic muscle disorders have one of the highest disease burdens and that treatments have remained unaffordable for most families.

鈥淐ongenital muscle diseases are also arguably the most individually impactful with many patients having a poor prognosis, requiring lifelong supportive care including mobility and respiratory support and in severe cases are inevitably fatal.鈥

Alfred Health鈥檚 said a major hurdle to advancing outcomes was understanding the underlying molecular basis of the diseases, coupled with a need for patient-specific models to develop and test therapies.

鈥淢uch of this clinical uncertainty stems from a lack of insight into the disease, which requires innovative thinking and investment into additional programs that can advance beyond genomics.鈥

A national, multidisciplinary network including paediatric neurologists, pathologists, scientists and patient advocacy groups have been assembled for the biobank project. Key collaborators include the Australian Neuromuscular Disease Registry, the Women鈥檚 and Children鈥檚 黑料吃瓜群网 in Adelaide, Monash Health, the University of Melbourne, The Royal Children鈥檚 黑料吃瓜群网, Children鈥檚 Health Queensland, Sydney Children鈥檚 黑料吃瓜群网s Network, The Harry Perkins Institute in Western Australia, Muscular Dystrophy Australia and the Fred Liuzzi Foundation.

Image credit: iStock.com/nevio3

Related News

Victoria's Q3 median ED wait times the lowest on record

Victoria's quarter three performance data (January–March) has shown improvement across...

Irregularities in a clinician's cases prompt 15-month lookback

St Vincent's 黑料吃瓜群网 Sydney has detailed a 15-month lookback review — prompted by...

Two researchers receive $899,000 in cardiovascular funding

In heart-related news this Heart Week (5–11 May), two University of Newcastle researchers...



Content from other channels on our network


  • All content Copyright 漏 2025 黑料吃瓜群网-Farrow Pty Ltd